Prednisolone
- PDF / 169,972 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 17 Downloads / 143 Views
1 S
Low bone mass: 2 case reports In a case report, an approximately 21-year-old woman and an approximately 31-year-old man were described, who exhibited low bone mass during treatment with prednisolone for Crohn’s disease (CD) [routes, duration of treatments to reactions onset and outcomes not stated]. Case 1: An approximately 21-year-old woman, who was diagnosed with CD in 2014, was initially managed with subtotal colectomy and ileal resection. She had been receiving prednisolone 24 mg/day, azathioprine [Imuran] and unspecified tumour necrosis factor inhibitor. Subsequently, she exhibited low bone mass secondary to prednisolone, and was treated with ibandronic acid [ibandronate] for 2 years. At the age of 23 years, she was admitted due to back pain. Dual energy X-ray absorptiometry (DXA) showed body mass density (BMD) of L1-L4 as 0.883 g/cm2 with Z score of -2.4DS. An X-ray of the spine showed L2-compression. Hence, her treatment was changed from ibandronic acid to teriparatide. Case 2: An approximately 31-year-old man, who was diagnosed with CD in 2015, underwent right hemicolectomy and ileal resection in 2017. He had been receiving treatment with prednisolone 4 mg/day and azathioprine [Imuran]. Subsequently, he exhibited low bone mass secondary to prednisolone, and was treated with risedronic acid for 2 years. At the age of 33 years, he was admitted for check-up. He had low bone density, and DXA showed BMD of L1-L4 as 0.848 g/cm2 with Z-score of -3.1 DS. The BMD of left hip was 0.678 g/cm2 with Z-score of -2.6DS, which was indicative of partial response to bisphosphonates. Hence, his treatment was changed to teriparatide. Soare I, et al. Management of low bone mass in young patients with Crohn disease after bisphosphonates: What’s next? Journal of Gastrointestinal and Liver Diseases 27 803497739 (Suppl. 3): 20 abstr. 41, Sep 2018. Available from: URL: https://www.jgld.ro/jgld/index.php/jgld/supplements [abstract]
0114-9954/20/1818-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 22 Aug 2020 No. 1818
Data Loading...
